throbber
Naloxone: Effects and Side Effects
`
`Gregory W. Terman M.D., Ph.D.
`Professor
`Department of Anesthesiology and Pain Medicine
`and the Graduate Program in Neurobiology
`Mayday Pain and Society Fellow
`University of Washington
`Seattle, Washington
`
`98195
`
`gwt@u.washington.edu
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 1
`
`

`

`Naloxone: Effects and Side Effects
`
`Specificity
`Toxicology
`Unmasking Disease
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 2
`
`

`

`Naloxone: Effects and Side Effects
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 3
`
`

`

`Naloxone: Effects and Side Effects
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 4
`
`

`

`Naloxone: Effects and Side Effects
`
`Am. J. Med. Sci. 245: 23-30, 1963
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 5
`
`

`

`Naloxone: Effects and Side Effects
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 6
`
`

`

`Naloxone: Effects and Side Effects
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 7
`
`

`

`Naloxone: Effects and Side Effects
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 8
`
`

`

`Naloxone: Effects and Side Effects
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 9
`
`

`

`Naloxone: Effects and Side Effects
`
`Specificity
`Toxicology
`Unmasking Disease
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 10
`
`

`

`Naloxone: Effects and Side Effects
`
`Toxicology in Rats:
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 11
`
`

`

`Naloxone: Effects and Side Effects
`
`Toxicology in People:
`Packaged 0.4 mg/ml and recommended at 0.4-0.8 mg IV.
`We treat opiate overdose in hospital with 0.04 mg IV
`with repeated doses q2 min as necessary.
`In opiate naïve patients without pain IV doses up to 5.4
`mg/kg boluses and 4 mg/kg/h have been administered
`without adverse effects (Clarke et al., Emerg Med J 22:
`616-616, 2005) (although mild elevations in blood
`pressure and decreased performance on memory tests
`have been reported with doses over 20 mg)
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 12
`
`

`

`Naloxone: Effects and Side Effects
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 13
`
`

`

`Naloxone: Effects and Side Effects
`
`Specificity
`Toxicology
`Unmasking Disease
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 14
`
`

`

`Naloxone: Effects and Side Effects
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 15
`
`

`

`Naloxone: Effects and Side Effects
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 16
`
`

`

`Naloxone: Effects and Side Effects
`Opiate Withdrawal:
`
`Terman et al, British Journal of Pharmacology, 2004
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 17
`
`

`

`Naloxone: Effects and Side Effects
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 18
`
`

`

`Naloxone: Effects and Side Effects
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 19
`
`

`

`Naloxone: Effects and Side Effects
`Cardiovascular effects
`Withdrawal induced catecholamine release (e.g., sweating)
`Tachycardia or other arrhythmia (myocardial
`ischemia) morbidity
`In patients with other drugs on board (e.g.,
`cocaine)
`In patients with pre-existing cardiac disease
`In patients with hypoxia and/or hypercarbia
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 20
`
`

`

`Naloxone: Effects and Side Effects
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 21
`
`

`

`Naloxone: Effects and Side Effects
`Cardiovascular effects
`Withdrawal induced catecholamine release (e.g., sweating)
`Tachycardia or other arrhythmia (myocardial
`ischemia) morbidity
`In patients with other drugs on board (e.g.,
`cocaine)
`In patients with pre-existing cardiac disease
`In patients with hypoxia and/or hypercarbia
`Hypertension morbidity (e.g., vascular aneurysms)
`Pulmonary edema (e.g., in heart failure)
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 22
`
`

`

`Naloxone: Effects and Side Effects
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 23
`
`

`

`Naloxone: Effects and Side Effects
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 24
`
`

`

`Naloxone: Effects and Side Effects
`Cardiovascular effects
`Withdrawal induced catecholamine release (e.g., sweating)
`Tachycardia or other arrhythmia (myocardial
`ischemia) morbidity
`In patients with other drugs on board (e.g.,
`cocaine)
`In patients with pre-existing cardiac disease
`In patients with hypoxia and/or hypercarbia
`Hypertension morbidity (e.g., vascular aneurysms)
`Pulmonary edema (e.g., in heart failure) –
`perhaps most commonly post-obstructive
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 25
`
`

`

`Naloxone: Effects and Side Effects
`Seizure effects
`May lower seizure thresholds for patients with prior
`seizure disorder or immediately post-ictal (i.e., after a
`seizure).
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 26
`
`

`

`Naloxone: Effects and Side Effects
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 27
`
`

`

`Naloxone: Effects and Side Effects
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 28
`
`

`

`Naloxone: Effects and Side Effects
`Seizure effects
`Theoretically, may lower seizure thresholds for patients
`with prior seizure disorder or immediately post-ictal (i.e.,
`after a seizure).
`May unmask seizures from other drugs on board (e.g.,
`cocaine).
`May unmask seizures due to hypoxia or hypercarbia.
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 29
`
`

`

`Naloxone: Effects and Side Effects
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 30
`
`

`

`Naloxone: Effects and Side Effects
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 31
`
`

`

`Naloxone: Effects and Side Effects
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 32
`
`

`

`Naloxone: Effects and Side Effects
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 33
`
`

`

`Naloxone: Effects and Side Effects
` Specificity (Amazing)
` Toxicology (Forgiving)
` Unmasking Disease: Concerns
` Opiate Dependence (Withdrawal)
` Co-ingested Substances
` Hypoxemia/Hypercarbia
` Arrythmias
` Seizures
` Post-Obstructive Pulmonary Edema
` Unrecognized Re-narcotization (perhaps worse with long–
`acting prescription meds than with other opiates)
` Pain
`
`Adapt & Opiant Exhibit 2024
`Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.
`IPR2019-00699
`Page 34
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket